Clinical Trial Update: Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating 225Ac-PSMA-617 in men with PSMA-positive prostate cancer, including castration-resistant cases; the study is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 225Ac-PSMA-617 (PSMA-617 radiolabeled with Actinium-225)

Snippet

Sponsor: Endocyte | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 1 | Status: RECRUITING